Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
AbstractThe main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies. View Full-Text
Share & Cite This Article
Abenavoli, L.; Falalyeyeva, T.; Boccuto, L.; Tsyryuk, O.; Kobyliak, N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals 2018, 11, 104.
Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals. 2018; 11(4):104.Chicago/Turabian Style
Abenavoli, Ludovico; Falalyeyeva, Tetyana; Boccuto, Luigi; Tsyryuk, Olena; Kobyliak, Nazarii. 2018. "Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease." Pharmaceuticals 11, no. 4: 104.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.